Marker antibodies in scleroderma and polymyositis: Clinical associations
- 59 Downloads
Sera of 34 patients with progressive systemic sclerosis and of 11 patients with polymyositis/dermatomyositis (PM/DM) were analyzed by the immunoblotting technique for the presence of marker antibodies. The presence of anti-centromere, anti-Topoisomerase-I (anti-Topo-I) and anti-Jo-1 antibodies was found to be highly specific for the CREST syndrome, diffuse scleroderma and PM/DM, respectively, but only of limited sensitivity (78, 44 and 45%, respectively). Anti-Topo-I positive diffuse scleroderma patients had a more severe disease (digital pitting scars and renal insufficency) than anti-Topo-I negative diffuse scleroderma patients. Anti-Jo-1 was associated with interstitial lung disease. Longitudinal studies showed a constant antibody pattern. Our results confirm the clinical usefulness of these marker antibodies.
Key wordsAntinuclear Antibodies Immunoblotting Scleroderma Polymyositis
Unable to display preview. Download preview PDF.
- 12.Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980, 23, 581–590.Google Scholar
- 22.McCarty, G.A., Rice, J.R., Bembe, M.L., Barada, R.A. Anricentromere antibody: clinical correlations and association with favourable prognosis in patients with scleroderma variants. Arthritis Rheum 1983, 26, 1–7.Google Scholar